How I treat patients with systemic sclerosis in clinical practice

Autoimmunity Reviews

Volumn 16, Issue 10, 2017, Pages 1024-1028

  Rossi, Daniela ^a,b   Zanatta, Elisabetta ^c   Marson, Piero ^c   Sciascia, Savino ^a,b   Polito, Pamela ^c   Roccatello, Dario ^a,b   Cozzi, Franco ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b S GIOVANNI BOSCO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTIFIBROTIC AGENT; BERAPROST; BOSENTAN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FLUOXETINE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; MACITENTAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROKINETIC AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; RIOCIGUAT; SILDENAFIL; STEROID; TADALAFIL; TOCILIZUMAB; TREPROSTINIL; VARDENAFIL; VASOACTIVE AGENT; VASODILATOR AGENT;

AUTOIMMUNITY; BLOATING; CLINICAL FEATURE; CLINICAL PRACTICE; DYSPHAGIA; ESOPHAGUS STENOSIS; ESOPHAGUS ULCER; FIBROSIS; FINGER ULCER; GASTROESOPHAGEAL REFLUX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; PRACTICE GUIDELINE; PSEUDOOBSTRUCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SCLERODERMA RENAL CRISIS; SKIN DISEASE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; IMMUNOLOGY;

HUMANS; SCLERODERMA, SYSTEMIC;

EID: 85028341313     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.018     Document Type: Review

References (82)

1. Desbois, A.C., Cacoub, P., Systemic sclerosis: an update in 2016. Autoimmun Rev 15 (2016), 417–426.
2. Ferri, C., Sebastiani, M., Lo Monaco, A., Iudici, M., Giuggioli, D., Furini, F., et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 13 (2014), 1026–1034.
3. Bryan, C., Howard, Y., Brennan, P., et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three diseases factors at first visit. Arthritis Rheum 42 (1999), 2660–2665.
4. Tyndall, A.J., Bannert, B., Cozzi, F., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis, 15, 2010.
5. Avouac, J., Kowal-Bielecka, O., Landewe, R., et al. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 68 (2009), 629–634.
6. Kowal-Bielecka, O., Landewé, R., Avouac, J., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68 (2009), 620–628.
7. Kowal-Bielecka, Otylia, Fransen, Jaap, Avouac, Jerome, Becker, Mike, Kulak, Agnieszka, Allanore, Yannick, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 0 (2016), 1–13.
8. Thompson, A.E., Shea, B., Welch, V., et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44 (2001), 1841–1847.
9. Ettinger, W.H., Wise, R.A., Schaffhauser, D., et al. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 77 (1984), 451–456.
10. Kahan, A., Weber, S., Amor, B., et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). Eur Heart J 4:Suppl. C (1983), 123–129.
11. Kahan, A., Foult, J.M., Weber, S., et al. Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon. Eur Heart J 6 (1985), 702–705.
12. Kahan, A., Amor, B., Menkès, C.J., et al. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Angiology 38 (1987), 333–337.
13. Rademaker, M., Cooke, E.D., Almond, N.E., et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298 (1989), 561–564.
14. Rodeheffer, R.J., Rommer, J.A., Wigley, F., et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 308 (1983), 880–883.
15. Meyrick Thomas, R.H., Rademaker, M., Grimes, S.M., et al. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 117 (1987), 237–241.
16. Roustit, M., Blaise, S., Allanore, Y., et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72 (2013), 1696–1699.
17. Herrick, A.L., van den Hoogen, F., Gabrielli, A., et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63 (2011), 775–782.
18. Fries, R., Shariat, K., von Wilmowsky, H., et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112 (2005), 2980–2985.
19. Schiopu, E., Hsu, V.M., Impens, A.J., et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 36 (2009), 2264–2268.
20. Shenoy, P.D., Kumar, S., Jha, L.K., et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 49 (2010), 2420–2428.
21. Agarwal, V., Ghosh, P., Sharma, A., et al. Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study (abstract). Arthritis Rheum, 62(Suppl. 10), 2010, S872.
22. Caglayan, E., Axmann, S., Hellmich, M., et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 172 (2012), 1182–1184.
23. Coleiro, B., Marshall, S.E., Denton, C.P., et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40 (2001), 1038–1043.
24. Wigley, F.M., Seibold, J.R., Wise, R.A., et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19 (1992), 1407–1414.
25. Wigley, F.M., Wise, R.A., Seibold, J.R., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120 (1994), 199–206.
26. Black, C.M., Halkier-Sørensen, L., Belch, J.J., et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37 (1998), 952–960.
27. Seibold, J.R., Wigley, F., Schiopu, E., et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study [abstract]. Arthritis Rheum, 63(10 Suppl), 2011, S968.
28. Tingey, T., Shu, J., Smuczek, J., et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 65 (2013), 1460–1471.
29. Korn, J.H., Mayes, M., Matucci Cerinic, M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004), 3985–3993.
30. Matucci-Cerinic, M., Denton, C.P., Furst, D.E., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70 (2011), 32–38.
31. Pulido, T., Adzerikho, I., Channick, R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 (2013), 809–818.
32. Ghofrani, H.A., Distler, O., Gerhardt, F., et al. Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154:Suppl. 1 (2011), S20–33.
33. Taichman, D.B., Ornelas, J., Chung, L., et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 146 (2014), 449–475.
34. Badesch, D.B., Tapson, V.F., McGoon, M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000), 425–434.
35. van den Hoogen, F.H., Boerbooms, A.M., Swaak, A.J., et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 (1996), 364–372.
36. Pope, J.E., Bellamy, N., Seibold, J.R., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 (2001), 1351–1358.
37. Johnson, S.R., Feldman, B.M., Pope, J.E., et al. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 36 (2009), 323–329.
38. Lateef, O., Shakoor, N., Balk, R.A., Methotrexate pulmonary toxicity. Expert Opin Drug Saf 4 (2005), 723–730.
39. Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006), 2655–2666.
40. Hoyles, R.K., Ellis, R.W., Wellsbury, J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54 (2006), 3962–3970.
41. Goldin, J., Elashoff, R., Kim, H.J., et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136 (2009), 1333–1340.
42. Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034.
43. Roth, M.D., Tseng, C.H., Clements, P.J., et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 63 (2011), 2797–2808.
44. Lynch, J.P. III, McCune, W.J., Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 155 (1997), 395–420.
45. Burt, R.K., Shah, S.J., Dill, K., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378 (2011), 498–506.
46. van Laar, J.M., Farge, D., Sont, J.K., et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311 (2014), 2490–2498.
47. Lopez-Ovejero, J.A., Saal, S.D., D'Angelo, W.A., et al. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 300 (1979), 1417–1419.
48. Steen, V.D., Costantino, J.P., Shapiro, A.P., et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113 (1990), 352–357.
49. Steen, V.D., Medsger, T.A. Jr., Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133 (2000), 600–603.
50. Teixeira, L., Mouthon, L., Mahr, A., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 67 (2008), 110–116.
51. Guillevin, L., Bérezné, A., Seror, R., et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 51 (2012), 460–467.
52. Steen, V.D., Medsger, T.A. Jr., Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41 (1998), 1613–1619.
53. Pakozdi, A., Wilson, H., Black, C.M., et al. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. Clin Exp Rheumatol 27:Suppl. 54 (2009), 5–8.
54. Chiba, N., De Gara, C.J., Wilkinson, J.M., et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112 (1997), 1798–1810.
55. Donnellan, C., Sharma, N., Preston, C., et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev(2), 2005, Cd003245.
56. Sigterman, K.E., van Pinxteren, B., Bonis, P.A., et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev, 5, 2013, Cd002095.
57. Ali, T., Roberts, D.N., Tierney, W.M., Long-term safety concerns with proton pump inhibitors. Am J Med 122 (2009), 896–903.
58. Acosta, A., Camilleri, M., Prokinetics in gastroparesis. Gastroenterol Clin North Am 44 (2015), 97–111.
59. Parodi, A., Sessarego, M., Greco, A., et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 103 (2008), 1257–1262.
60. Marie, I., Ducrotté, P., Denis, P., et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford) 48 (2009), 1314–1319.
61. Khanna, D., Denton, C.P., Jahreis, A., et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387 (2016), 2630–2640.
62. Clements, P.J., Tashkin, D., Roth, M., et al. The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheumatol, 67(Suppl. 10), 2015.
63. LeRoy, E.C., Black, C., Fleischmajer, R., Jablonskas, S., Kireg, T., Medsger, T.A. Jr., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 (1988), 202–205.
64. Domsic, D.T., Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol 26 (2014), 646–652.
65. Chaisson, N.F., Hassoun, P.M., Systemic sclerosis-associated pulmonary arterial hypertension. Chest 144 (2013), 1346–1356.
66. Ferri, C., Valentini, G., Cozzi, F., Sebastiani, M., Michelassi, M., La Montagna, G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 8 (2002), 139–153.
67. Le EN, Wigley F.M., Shah, A.A., Boin, F., Hummers, L.K., Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70 (2011), 1104–1107.
68. Cozzi, F., Marson, P., Rosada, M., De Silvestro, G., Bullo, A., Punzi, L., et al. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity. Transfus Apher Sci 25 (2001), 25–31.
69. Wigley, F.M., Seibold, J.R., Wise, R.A., DA, McCloskey, Dole, W.P., Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19 (1992), 1407–1414.
70. Cozzi, F., Pigatto, E., Rizzo, M., Favaro, M., Zanatta, E., Cardarelli, S., et al. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case–control study. Clin Rheumatol 32 (2013), 679–683.
71. Valenzuela, A., Chung, L., Management of calcinosis associated with systemic sclerosis. Curr Treat Options Rheum 2 (2016), 85–96.
72. Nagaraja, V., ZH, McMahan, Getzug, T., Khanna, D., Management of gastrointestinal involvement in scleroderma. Curr Treat Opt Rheumatol 1 (2015), 82–105.
73. Wang, S.J., La JL, Chen D.Y., Chen, Y.H., Hsieh, T.Y., Lin, W.Y., Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 21 (2002), 43–45.
74. Grace, E., Shaw, C., Whelan, K., Andreyev, H.J., Review article: small intestinal bacterial overgrowth—prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38 (2013), 674–688.
75. Sobanski, V., Launay, D., Hachulla, E., Humbert, M., Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (Ssc-PAH). Curr Rheumatol Rep, 18, 2016, 10.
76. Humbert, M., Coghlan, J.G., Ghofrani, H.A., Grimminger, F., He, J.G., Riemekasten, G., et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 76 (2017), 422–426.
77. Tyndall, A.J., Bannert, B., Vonk, M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 (2010), 1809–1815.
78. Owen, C., Ngian, G., Elford, Moore, O., Stevens, W., Nikpour, M., et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol 34:Suppl. 100 (2016), 170–176.
79. Bosello, S.L., De Luca, G., Rucco, M., Berardi, G., Falcione, M., Danza, F.M., et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 44 (2015), 428–436.
80. Dinser, R., Frerix, M., Meier, F.M., Klingelb, K., Rolf, A., Endocardial and myocardial involvement in systemic sclerosis – is there a relevant inflammatory component?. Joint Bone Spine 80 (2013), 320–323.
81. Pieroni, P., DeSantis, M., Zizzo, G., Bosello, S.L., Smaldone, C., Campioni, M., et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 43 (2014), 526–535.
82. Cozzi, F., Marson, P., Cardarelli, S., Favaro, M., Tison, T., Tonello, M., et al. Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant 27 (2012), 4398–4403.